EBMT 2023 | Assessing the cost-effectiveness of CAR-T therapy in adult patients with R/R ALL
Monia Marchetti
• 26 Apr 2023
Monia Marchetti, MD, Azienda Ospedaliera SS. Antonio e. Biagio e Cesare Arrigo, Alessandria, Italy, discusses the cost-effectiveness of CAR-T therapy in patients with adult acute lymphoblastic leukemia (ALL). Prof. Marchetti emphasizes that although CAR-T-cell therapy can be costly, it has demonstrated high value for cost in several studies due to its capacity to significantly improve patient outcomes. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Gilead consultancy fees.
